Skip to Content

Warfarin Dosage

Applies to the following strength(s): 4 mg ; 1 mg ; 2 mg ; 5 mg ; 7.5 mg ; 10 mg ; 2.5 mg ; 3 mg ; 6 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for Prevention of Thromboembolism in Atrial Fibrillation

Initial dose: 2 to 5 mg orally once a day
Maintenance dose: 2 to 10 mg orally once a day

Target INR: 2.5 (range: 2 to 3)

Duration of therapy: Indefinite

Comments:
-For patients with atrial fibrillation (AF) and prosthetic heart valves, target INR may be increased depending on valve type, valve position, and patient factors.
-Initial dose is influenced by age, race, body weight, gender, concomitant medications, comorbidities, genetic variation, and possibly other factors.
-Dosage and administration must be individualized according to the patient's INR and condition being treated.

Use: Prophylaxis and treatment of thromboembolic complications associated with AF.

Usual Adult Dose for Thromboembolic Stroke Prophylaxis

Initial dose: 2 to 5 mg orally once a day
Maintenance dose: 2 to 10 mg orally once a day

Target INR: 2.5 (range: 2 to 3)

Duration of therapy: Indefinite

Comments:
-For patients with atrial fibrillation (AF) and prosthetic heart valves, target INR may be increased depending on valve type, valve position, and patient factors.
-Initial dose is influenced by age, race, body weight, gender, concomitant medications, comorbidities, genetic variation, and possibly other factors.
-Dosage and administration must be individualized according to the patient's INR and condition being treated.

Use: Prophylaxis and treatment of thromboembolic complications associated with AF.

Usual Adult Dose for Myocardial Infarction

Initial dose: 2 to 5 mg orally once a day
Maintenance dose: 2 to 10 mg orally once a day

INR: 2 to 3

Duration of therapy: At least 3 months after myocardial infarction

Comments:
-Initial dose is influenced by age, race, body weight, gender, concomitant medications, comorbidities, genetic variation, and possibly other factors.
-Dosage and administration must be individualized according to the patient's INR and condition being treated.

Use: Reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Usual Adult Dose for Myocardial Infarction - Prophylaxis

Initial dose: 2 to 5 mg orally once a day
Maintenance dose: 2 to 10 mg orally once a day

INR: 2 to 3

Duration of therapy: At least 3 months after myocardial infarction

Comments:
-Initial dose is influenced by age, race, body weight, gender, concomitant medications, comorbidities, genetic variation, and possibly other factors.
-Dosage and administration must be individualized according to the patient's INR and condition being treated.

Use: Reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Usual Adult Dose for Deep Vein Thrombosis - Prophylaxis

Initial dose: 2 to 5 mg orally once a day
Maintenance dose: 2 to 10 mg orally once a day

Target INR: 2.5 (range: 2 to 3)

Duration of therapy:
-Deep venous thrombosis (DVT) or pulmonary embolism (PE) secondary to a reversible risk factor: 3 months
-Unprovoked DVT or PE: At least 3 months; evaluate risk-benefit ratio of long-term treatment after 3 months.
-Two episodes of unprovoked DVT or PE: Indefinite; periodically reassess risk-benefit ratio of continuing such treatment.

Comments:
-Initial dose is influenced by age, race, body weight, gender, concomitant medications, comorbidities, genetic variation, and possibly other factors.
-Dosage and administration must be individualized according to the patient's INR and condition being treated.

Use: Prophylaxis and treatment of venous thrombosis and PE.

Usual Adult Dose for Pulmonary Embolism

Initial dose: 2 to 5 mg orally once a day
Maintenance dose: 2 to 10 mg orally once a day

Target INR: 2.5 (range: 2 to 3)

Duration of therapy:
-Deep venous thrombosis (DVT) or pulmonary embolism (PE) secondary to a reversible risk factor: 3 months
-Unprovoked DVT or PE: At least 3 months; evaluate risk-benefit ratio of long-term treatment after 3 months.
-Two episodes of unprovoked DVT or PE: Indefinite; periodically reassess risk-benefit ratio of continuing such treatment.

Comments:
-Initial dose is influenced by age, race, body weight, gender, concomitant medications, comorbidities, genetic variation, and possibly other factors.
-Dosage and administration must be individualized according to the patient's INR and condition being treated.

Use: Prophylaxis and treatment of venous thrombosis and PE.

Usual Adult Dose for Deep Vein Thrombosis - First Event

Initial dose: 2 to 5 mg orally once a day
Maintenance dose: 2 to 10 mg orally once a day

Target INR: 2.5 (range: 2 to 3)

Duration of therapy:
-Deep venous thrombosis (DVT) or pulmonary embolism (PE) secondary to a reversible risk factor: 3 months
-Unprovoked DVT or PE: At least 3 months; evaluate risk-benefit ratio of long-term treatment after 3 months.
-Two episodes of unprovoked DVT or PE: Indefinite; periodically reassess risk-benefit ratio of continuing such treatment.

Comments:
-Initial dose is influenced by age, race, body weight, gender, concomitant medications, comorbidities, genetic variation, and possibly other factors.
-Dosage and administration must be individualized according to the patient's INR and condition being treated.

Use: Prophylaxis and treatment of venous thrombosis and PE.

Usual Adult Dose for Deep Vein Thrombosis - Recurrent Event

Initial dose: 2 to 5 mg orally once a day
Maintenance dose: 2 to 10 mg orally once a day

Target INR: 2.5 (range: 2 to 3)

Duration of therapy:
-Deep venous thrombosis (DVT) or pulmonary embolism (PE) secondary to a reversible risk factor: 3 months
-Unprovoked DVT or PE: At least 3 months; evaluate risk-benefit ratio of long-term treatment after 3 months.
-Two episodes of unprovoked DVT or PE: Indefinite; periodically reassess risk-benefit ratio of continuing such treatment.

Comments:
-Initial dose is influenced by age, race, body weight, gender, concomitant medications, comorbidities, genetic variation, and possibly other factors.
-Dosage and administration must be individualized according to the patient's INR and condition being treated.

Use: Prophylaxis and treatment of venous thrombosis and PE.

Usual Adult Dose for Pulmonary Embolism - First Event

Initial dose: 2 to 5 mg orally once a day
Maintenance dose: 2 to 10 mg orally once a day

Target INR: 2.5 (range: 2 to 3)

Duration of therapy:
-Deep venous thrombosis (DVT) or pulmonary embolism (PE) secondary to a reversible risk factor: 3 months
-Unprovoked DVT or PE: At least 3 months; evaluate risk-benefit ratio of long-term treatment after 3 months.
-Two episodes of unprovoked DVT or PE: Indefinite; periodically reassess risk-benefit ratio of continuing such treatment.

Comments:
-Initial dose is influenced by age, race, body weight, gender, concomitant medications, comorbidities, genetic variation, and possibly other factors.
-Dosage and administration must be individualized according to the patient's INR and condition being treated.

Use: Prophylaxis and treatment of venous thrombosis and PE.

Usual Adult Dose for Pulmonary Embolism - Recurrent Event

Initial dose: 2 to 5 mg orally once a day
Maintenance dose: 2 to 10 mg orally once a day

Target INR: 2.5 (range: 2 to 3)

Duration of therapy:
-Deep venous thrombosis (DVT) or pulmonary embolism (PE) secondary to a reversible risk factor: 3 months
-Unprovoked DVT or PE: At least 3 months; evaluate risk-benefit ratio of long-term treatment after 3 months.
-Two episodes of unprovoked DVT or PE: Indefinite; periodically reassess risk-benefit ratio of continuing such treatment.

Comments:
-Initial dose is influenced by age, race, body weight, gender, concomitant medications, comorbidities, genetic variation, and possibly other factors.
-Dosage and administration must be individualized according to the patient's INR and condition being treated.

Use: Prophylaxis and treatment of venous thrombosis and PE.

Usual Adult Dose for Prosthetic Heart Valves - Tissue Valves

Initial dose: 2 to 5 mg orally once a day
Maintenance dose: 2 to 10 mg orally once a day

Comments:
-Initial dose is influenced by age, race, body weight, gender, concomitant medications, comorbidities, genetic variation, and possibly other factors.
-Dosage and administration must be individualized according to the patient's INR and condition being treated.

Uses:
-Prophylaxis and treatment of thromboembolic complications in patients with a bileaflet mechanical valve or a Medtronic Hall (Minneapolis, MN) tilting disk valve in the aortic position who are in sinus rhythm and without left atrial enlargement (target INR: 2.5; range: 2 to 3).
-Prophylaxis and treatment of thromboembolic complications in patients with tilting disk valves and bileaflet mechanical valves in the mitral position (target INR: 3; range: 2.5 to 3.5).
-Prophylaxis and treatment of thromboembolic complications in patients with caged ball or caged disk valves (target INR: 3; range: 2.5 to 3.5).
-Prophylaxis and treatment of thromboembolic complications in patients with a bioprosthetic valve in the mitral position (target INR: 2.5; range: 2 to 3) for the first 3 months after valve insertion is recommended. If additional risk factors for thromboembolism are present (atrial fibrillation, previous thromboembolism, left ventricular dysfunction), a target INR of 2.5 (range: 2 to 3) is recommended.

Usual Adult Dose for Prosthetic Heart Valves - Mechanical Valves

Initial dose: 2 to 5 mg orally once a day
Maintenance dose: 2 to 10 mg orally once a day

Comments:
-Initial dose is influenced by age, race, body weight, gender, concomitant medications, comorbidities, genetic variation, and possibly other factors.
-Dosage and administration must be individualized according to the patient's INR and condition being treated.

Uses:
-Prophylaxis and treatment of thromboembolic complications in patients with a bileaflet mechanical valve or a Medtronic Hall (Minneapolis, MN) tilting disk valve in the aortic position who are in sinus rhythm and without left atrial enlargement (target INR: 2.5; range: 2 to 3).
-Prophylaxis and treatment of thromboembolic complications in patients with tilting disk valves and bileaflet mechanical valves in the mitral position (target INR: 3; range: 2.5 to 3.5).
-Prophylaxis and treatment of thromboembolic complications in patients with caged ball or caged disk valves (target INR: 3; range: 2.5 to 3.5).
-Prophylaxis and treatment of thromboembolic complications in patients with a bioprosthetic valve in the mitral position (target INR: 2.5; range: 2 to 3) for the first 3 months after valve insertion is recommended. If additional risk factors for thromboembolism are present (atrial fibrillation, previous thromboembolism, left ventricular dysfunction), a target INR of 2.5 (range: 2 to 3) is recommended.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

Use with caution

Dose Adjustments

The following factors may necessitate a dose reduction: weight loss, acute illness, or smoking cessation.
The following factors may necessitate a dose increase: weight gain, diarrhea, or vomiting.

Dosing Recommendations with Consideration of Genotype:
Genetic variations in the CYP450 2C9 and vitamin K epoxide reductase complex 1 (VKORC1) enzymes can significantly influence patient response to this drug as indicated by the prothrombin time (PT)/INR. Lower initial doses have been suggested for patients with these genetic variations due to increased risk of bleeding. Range of expected maintenance daily doses based on CYP450 2C9 and VKORC1 genotypes:
-VKORC1 GG and CYP450 2C9 *1/*1: 5 to 7 mg
-VKORC1 AG and CYP450 2C9 *1/*1: 5 to 7 mg
-VKORC1 AA and CYP450 2C9 *1/*1: 3 to 4 mg
-VKORC1 GG and CYP450 2C9 *1/*2: 5 to 7 mg
-VKORC1 AG and CYP450 2C9 *1/*2: 3 to 4 mg
-VKORC1 AA and CYP450 2C9 *1/*2: 3 to 4 mg
-VKORC1 GG and CYP450 2C9 *1/*3: 3 to 4 mg
-VKORC1 AG and CYP450 2C9 *1/*3: 3 to 4 mg
-VKORC1 AA and CYP450 2C9 *1/*3: 0.5 to 2 mg
-VKORC1 GG and CYP450 2C9 *2/*2: 3 to 4 mg
-VKORC1 AG and CYP450 2C9 *2/*2: 3 to 4 mg
-VKORC1 AA and CYP450 2C9 *2/*2: 0.5 to 2 mg
-VKORC1 GG and CYP450 2C9 *2/*3: 3 to 4 mg
-VKORC1 AG and CYP450 2C9 *2/*3: 0.5 to 2 mg
-VKORC1 AA and CYP450 2C9 *2/*3: 0.5 to 2 mg
-VKORC1 GG and CYP450 2C9 *3/*3: 0.5 to 2 mg
-VKORC1 AG and CYP450 2C9 *3/*3: 0.5 to 2 mg
-VKORC1 AA and CYP450 2C9 *3/*3: 0.5 to 2 mg
Note: In addition to genetic variation, initial dose is influenced by age, race, body weight, gender, concomitant medications, comorbidities, and possibly other factors.

Patients with CYP450 2C9 *1/*3, *2/*2, *2/*3, and *3/*3 alleles may take up to 4 weeks to achieve maximum INR with a given dose regimen.

Conversion from Heparin and Other Anticoagulants:
Heparin:
-Conversion to this drug may begin concomitantly with heparin or may be delayed 3 to 6 days.
-Continue full-dose heparin with this drug and overlap for 4 to 5 days and until the desired therapeutic response as determined by INR has been achieved, at which point heparin may be discontinued.

Other anticoagulants:
-Consult the manufacturer product information of other anticoagulants to determine appropriate conversion to this drug.

Precautions

US BOXED WARNING:
-BLEEDING RISK: This drug can cause major or fatal bleeding. Perform regular monitoring of INR in all treated patients. Drugs, dietary changes, and other factors affect INR levels achieved with this drug. Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding.

NARROW THERAPEUTIC INDEX:
-This drug should be considered a narrow therapeutic index (NTI) drug as small differences in dose or blood concentrations may lead to serious therapeutic failures or adverse drug reactions.
Recommendations:
- Generic substitution should be done cautiously, if at all, as current bioequivalence standards are generally insufficient for NTI drugs.
-Additional and/or more frequent monitoring should be done to ensure receipt of an effective dose while avoiding unnecessary toxicities.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Consult the latest guidelines regarding duration and intensity of anticoagulation for the indicated conditions.
-This drug should be taken at the same time each day.
-In emergencies, initiate this drug with heparin.
-In general, anticoagulant therapy should be continued until the risk of thrombosis and embolism has passed.

Storage requirements: Protect from light.

Reconstitution/preparation techniques: Pregnant pharmacy and clinical personnel should avoid exposure to crushed or broken tablets.

General:
-This drug has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage.
-Various brands of this drug may not be bioequivalent.

Monitoring:
-Hematologic: Prothrombin time (PT)/INR (the manufacturer product information and institution-specific protocol should be consulted).
-Hepatic: Liver function tests at baseline

Patient advice:
-Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding.
-Encourage patients to eat a consistent amount of vitamin K.
-Inform patients that a missed dose should be taken as soon as possible on the same day, and not doubled the next day.
-Instruct patients to inform their doctor before they start any additional medications, including over-the-counter products, herbal remedies, and supplements.
-Advise females of reproductive potential to use effective contraception during treatment and for at least 1 month after the final dose.
-Advise patients to contact their doctor immediately if they think they are pregnant, to discuss pregnancy planning, and if they are considering breastfeeding.

Hide